Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

AbbVie

Deere & Company

Bulls seeking stock trades should focus on relative strength. Here are three stocks itching for new highs as the market sinks.

3 Top Stock Trades for This Week

Air Products and Chemicals

Chubb

Illinois Tool Works

Medtronic

Philip Morris

SPDR S&P 500 ETF Trust

STAG Industrial

Stryker

Walmart

W. P. Carey

We provide a summary of upcoming ex-dividend dates in a quick reference table.

Upcoming Ex-Dividend Dates: March 16-31, 2022

Atlanta Braves Holdings Inc

Comcast

CVS Health

Paramount Global

By now you've gotten the memo that it's time to own value stocks, since value beats growth when consumer prices and interest rates rise.

Value investing is back: Here's how to dodge the losers and spot the winners — with five stocks to consider

Nektar Therapeutics

Bristol Myers Squibb Co (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have an update following the first analysis of the Phase 3 PIVOT IO-001 study of bempegaldesleukin combined with Opdivo (nivolumab) in previously untreated unresectable or metastatic melanoma.

Bristol Myers, Nektar Melanoma Doublet Therapy Trial Fails To Show Clinical Benefit

PRINCETON, N.J., & SAN FRANCISCO--(BUSINESS WIRE)---- $BMY #BEMPEG--BMS and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial

Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022

Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022

AstraZeneca

Some cheap stocks are worth investing in.

2 Top Dividend Stocks You Can Buy for Less Than $100 Per Share

GlaxoSmithKline

Johnson & Johnson

Merck

Novartis

Pfizer

As Viatris and other generic drug makers plunge, what should you buy instead? Consider these seven well-known drug stocks, all of which are good value in what's still a pricey market.

7 Drug Stocks to Consider After the Viatris Plunge

Amgen

Which pharmaceutical companies can rocket your portfolio right now? Let's take a look.

3 Dividend-Paying Pharmaceutical Stocks You Can't Ignore

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Participate in Upcoming Investor Conferences on March 16

Bristol Myers Squibb to Participate in Upcoming Investor Conferences on March 16

Alcoa

Chevron

Freeport-McMoRan

Coca-Cola

Lockheed Martin

Raytheon Technologies

It's hard to believe, but there are uptrend stocks out there. Investors just have to look for the strength that these stocks are showing.

8 Strong Uptrend Stocks to Buy on the Next Dip

Akebia Therapeutics

Amylyx Pharmaceuticals

Arena Pharmaceuticals

Ascendis Pharma

IMARA

Terns Pharmaceuticals

These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on InvestorPlace.

7 Biotech Stocks With Key Catalysts in March

Of the $17 billion in annual sales that will be lost to copycat drugs this year, a Bristol-Myers Squibb Co. ( BMY , Financial) cancer medication is in line to take the biggest hit.

Blockbusters From Bristol-Myers, AbbVie Losing Exclusivity

Bristol Myers' (BMY) immuno-oncology Opdivo gets FDA nod for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting in combination with platinum-doublet chemotherapy.

FDA Nods to Bristol Myers' (BMY) Opdivo for Additional Indication

Do Food and Drug Administration decisions—thumbs up or thumbs down—affect the stock prices of companies seeking drug approvals? We're likely to find out this month as several key drugs are about to be ruled on.

Key FDA Decisions Soon on Akebia, Bristol-Myers and Novartis Drugs

Bristol-Myers Squibb ( BMY , Financial) seems to be on track for a solid year in 2022, fueled by strong sales of core drugs Eliquis and Opdivo, as well as continued demand growth for their new products. The company's launch of Zeposia in the U.S. for ulcerative colitis has progressed smoothly, and they recently received European approval for the same during the past quarter.

Bristol-Myers Squibb: Eliquis and Opdivo Are Shining Stars

Eli Lilly

Sanofi

Can these health care stocks climb this month?

5 Health Care Stocks To Watch In March 2022

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. FDA Approves Opdivo with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer

Alexandria Real Estate Equities' (ARE) latest lease marks the second-largest life science lease in Alexandria's history and boosts its long-term strategic tie-up with Bristol Myers Squibb.

Alexandria (ARE) & Bristol Myers Boost Tie-Up With New Lease

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers

Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Early Participation Results, Upsizing and Early Settlement of Tender Offers

Bristol Myers Squibb Announces Early Participation Results, Upsizing and Early Settlement of Tender Offers

Partners Johnson & Johnson ( JNJ , Financial) and Legend Biotech Corp. ( LEGN , Financial) would probably agree that good things come to those who wait. The two pharma companies were rewarded for their patience when the Food and Drug Administration approved their CAR-T therapy this week.

Johnson & Johnson's Gain Could Be Bristol-Myers' Loss

Dragonfly receives a milestone payment from Bristol Myers Squibb for progression of its Phase 1 DF6002-001 study with a PK profile and peripheral PD consistent with preclinical models WALTHAM, Mass., March 1, 2022 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly") today announced the achievement of a Phase 1 clinical development milestone for the DF6002/BMS-9896415 IL-12 program.

Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. FDA Accepts for Priority Review BMS's Application for Opdivo Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer

We think that Bristol Myers Squibb stock currently is a better pick compared to its industry peer Johnson & Johnson stock, given its better growth prospects and comparatively lower valuation of 3.2x trailing revenues, compared to 4.5x for J&J. This valuation gap can be attributed to J&J's ability.

News for Bristol-Myers Stock (BMY)